First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy Anthony YapJustin F GainorMargaret K CallahanGerald S FalchookRussell K PachynskiPatricia LoRussoShivaani KummarGeoffrey T GibneyHoward A BurrisScott S TykodiOsama E RahmaTanguy Y SeiwertKyriakos P PapadopoulosMariela Blum MurphyHaeseong ParkAmanda HansonYasmin Hashambhoy-RamsayLara McGrathEllen HooperXiaoying XiaoHeather CohenMartin FanDaniel FelitskyCourtney HartRachel McCombKaren BrownAli SepahiJudith JimenezWeidong ZhangJohan BaeckHaley LakenRichard MurrayElizabeth TrehuChristopher J HarveyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Vopratelimab demonstrated a favorable safety profile alone and in combination with nivolumab. Efficacy was observed only in a subset of patients with a vopratelimab-specific pharmacodynamic biomarker. A potential predictive biomarker of response was identified, which is being prospectively evaluated in a randomized phase II non-small cell lung cancer trial. See related commentary by Lee and Fong, p. 3633.